US Stock MarketDetailed Quotes
BDRX Biodexa Pharmaceuticals
- 1.1900
- -0.0500-4.03%
Close May 17 16:00 ET
- 1.2400
- +0.0500+4.20%
Post 19:26 ET
5.22MMarket Cap-117P/E (TTM)
1.3700High1.1600Low487.46KVolume1.3700Open1.2400Pre Close622.74KTurnover23.14%Turnover RatioLossP/E (Static)4.38MShares16.320052wk High0.88P/B2.51MFloat Cap0.670052wk Low--Dividend TTM2.11MShs Float587200.0000Historical High--Div YieldTTM16.94%Amplitude0.6700Historical Low1.2770Avg Price1Lot Size
Biodexa Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | (FY)Dec 31, 2018 | |
|---|---|---|---|---|---|---|
| Total revenue | -45.49%381K | 20.93%699K | 68.51%578K | -49.11%343K | -65.22%674K | 1.94M |
| Operating revenue | -45.49%381K | 20.93%699K | 221.11%578K | -73.29%180K | -65.22%674K | --1.94M |
| Cost of revenue | -20.43%4.07M | 9.82%5.11M | -23.30%4.65M | -22.63%6.07M | -16.20%7.84M | 9.36M |
| Gross profit | 16.46%-3.69M | -8.24%-4.41M | 28.80%-4.08M | 20.14%-5.73M | 3.40%-7.17M | -7.42M |
| Operating expense | -4.25%4.33M | 54.69%4.52M | -40.92%2.92M | 19.21%4.95M | -5.58%4.15M | 4.39M |
| Selling and administrative expenses | -4.40%4.34M | 54.18%4.54M | -40.58%2.95M | 19.07%4.96M | -5.23%4.16M | --4.39M |
| -Selling and marketing expense | ---- | ---- | ---- | ---- | --323K | --0 |
| -General and administrative expense | -4.40%4.34M | 54.18%4.54M | -40.58%2.95M | 29.08%4.96M | -12.59%3.84M | --4.39M |
| Other operating expenses | 36.36%-14K | 8.33%-22K | -100.00%-24K | ---12K | ---- | ---- |
| Operating profit | 10.28%-8.01M | -27.64%-8.93M | 34.42%-7M | 5.72%-10.67M | 4.21%-11.32M | -11.82M |
| Net non-operating interest income expense | 275.00%42K | 45.45%-24K | -33.33%-44K | 62.92%-33K | 84.79%-89K | -585K |
| Non-operating interest income | 186.21%83K | --29K | --0 | -87.50%1K | 300.00%8K | --2K |
| Non-operating interest expense | -22.64%41K | 20.45%53K | 29.41%44K | -64.95%34K | -83.48%97K | --587K |
| Other net income (expense) | 4.06%487K | -50.00%468K | 107.33%936K | -12.77M | ||
| Gain on sale of security | 4.06%487K | -50.00%468K | 335.77%936K | ---397K | ---- | ---- |
| Special income (charges) | ---- | ---- | ---- | ---12.37M | --0 | --0 |
| -Less:Impairment of capital assets | ---- | ---- | ---- | --12.37M | --0 | --0 |
| Income before tax | 11.82%-7.49M | -39.01%-8.49M | 73.98%-6.11M | -114.87%-23.47M | 11.91%-10.92M | -12.4M |
| Income tax | 51.20%-406K | -28.79%-832K | 49.57%-646K | 28.24%-1.28M | 12.16%-1.79M | -2.03M |
| Net income | 7.54%-7.08M | -40.22%-7.66M | 75.39%-5.46M | -120.02%-22.19M | 32.90%-10.09M | -15.03M |
| Net income continuous Operations | 7.54%-7.08M | -40.22%-7.66M | 75.39%-5.46M | -142.82%-22.19M | 11.86%-9.14M | ---10.37M |
| Net income discontinuous operations | ---- | ---- | ---- | ---- | 79.69%-947K | ---4.66M |
| Minority interest income | ||||||
| Net income attributable to the parent company | 7.54%-7.08M | -40.22%-7.66M | 75.39%-5.46M | -120.02%-22.19M | 32.90%-10.09M | -15.03M |
| Preferred stock dividends | ||||||
| Other preferred stock dividends | 0 | 0 | 0 | |||
| Net income attributable to common stockholders | 7.54%-7.08M | -40.22%-7.66M | 75.39%-5.46M | -120.02%-22.19M | 32.90%-10.09M | -15.03M |
| Basic earnings per share | 98.71%-8 | -13.97%-620 | 86.87%-544 | -3.60%-4.14K | 89.84%-4K | -39.36K |
| Diluted earnings per share | 98.71%-8 | -13.97%-620 | 86.87%-544 | 5.85%-4.14K | 88.82%-4.4K | -39.36K |
| Dividend per share | ||||||
| Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg